Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Income (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Operating Income for 3 consecutive years, with $42.1 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 375.82% to $42.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Dec 2025, up 121.99% year-over-year, with the annual reading at $10.4 million for FY2025, 121.99% up from the prior year.
  • Operating Income for Q4 2025 was $42.1 million at Mereo BioPharma, up from -$10.0 million in the prior quarter.
  • The five-year high for Operating Income was $42.1 million in Q4 2025, with the low at -$15.3 million in Q4 2024.
  • Average Operating Income over 3 years is -$5.4 million, with a median of -$10.0 million recorded in 2024.
  • The sharpest move saw Operating Income plummeted 1480.02% in 2024, then soared 375.82% in 2025.
  • Over 3 years, Operating Income stood at -$7.1 million in 2023, then tumbled by 114.3% to -$15.3 million in 2024, then skyrocketed by 375.82% to $42.1 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $42.1 million, -$10.0 million, and -$10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.